Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts

Laure Frésard,Craig Smail,Nicole M Ferraro,Nicole A Teran,Xin Li,Kevin S Smith,Devon Bonner,Kristin D Kernohan,Shruti Marwaha,Zachary Zappala,Brunilda Balliu,Joe R Davis,Boxiang Liu,Cameron J Prybol,Jennefer N Kohler,Diane B Zastrow,Chloe M Reuter,Dianna G Fisk,Megan E Grove,Jean M Davidson,Taila Hartley,Ruchi Joshi,Benjamin J Strober,Sowmithri Utiramerur,Undiagnosed Diseases Network,Care4Rare Canada Consortium,Lars Lind,Erik Ingelsson,Alexis Battle,Gill Bejerano,Jonathan A Bernstein,Euan A Ashley,Kym M Boycott,Jason D Merker,Matthew T Wheeler,Stephen B Montgomery,David R Adams,Aaron Aday,Mercedes E Alejandro,Patrick Allard,Mahshid S Azamian,Carlos A Bacino,Eva Baker,Ashok Balasubramanyam,Hayk Barseghyan,Gabriel F Batzli,Alan H Beggs,Babak Behnam,Hugo J Bellen,Gerard T Berry,Anna Bican,David P Bick,Camille L Birch,Braden E Boone,Bret L Bostwick,Lauren C Briere,Elly Brokamp,Donna M Brown,Matthew Brush,Elizabeth A Burke,Lindsay C Burrage,Manish J Butte,Shan Chen,Gary D Clark,Terra R Coakley,Joy D Cogan,Heather A Colley,Cynthia M Cooper,Heidi Cope,William J Craigen,Precilla D'Souza,Mariska Davids,Jyoti G Dayal,Esteban C Dell'Angelica,Shweta U Dhar,Katrina M Dipple,Laurel A Donnell-Fink,Naghmeh Dorrani,Daniel C Dorset,Emilie D Douine,David D Draper,Annika M Dries,Laura Duncan,David J Eckstein,Lisa T Emrick,Christine M Eng,Gregory M Enns,Ascia Eskin,Cecilia Esteves,Tyra Estwick,Liliana Fernandez,Carlos Ferreira,Elizabeth L Fieg,Paul G Fisher,Brent L Fogel,Noah D Friedman,William A Gahl,Emily Glanton,Rena A Godfrey,Alica M Goldman,David B Goldstein,Sarah E Gould,Jean-Philippe F Gourdine,Catherine A Groden,Andrea L Gropman,Melissa Haendel,Rizwan Hamid,Neil A Hanchard,Frances High,Ingrid A Holm,Jason Hom,Ellen M Howerton,Yong Huang,Fariha Jamal,Yong-Hui Jiang,Jean M Johnston,Angela L Jones,Lefkothea Karaviti,David M Koeller,Isaac S Kohane,Donna M Krasnewich,Susan Korrick,Mary Koziura,Joel B Krier,Jennifer E Kyle,Seema R Lalani,C Christopher Lau,Jozef Lazar,Kimberly LeBlanc,Brendan H Lee,Hane Lee,Shawn E Levy,Richard A Lewis,Sharyn A Lincoln,Sandra K Loo,Joseph Loscalzo,Richard L Maas,Ellen F Macnamara,Calum A MacRae,Valerie V Maduro,Marta M Majcherska,May Christine V Malicdan,Laura A Mamounas,Teri A Manolio,Thomas C Markello,Ronit Marom,Martin G Martin,Julian A Martínez-Agosto,Thomas May,Allyn McConkie-Rosell,Colleen E McCormack,Alexa T McCray,Thomas O Metz,Matthew Might,Paolo M Moretti,Marie Morimoto,John J Mulvihill,David R Murdock,Jennifer L Murphy,Donna M Muzny,Michele E Nehrebecky,Stan F Nelson,J Scott Newberry,John H Newman,Sarah K Nicholas,Donna Novacic,Jordan S Orange,James P Orengo,J Carl Pallais,Christina Gs Palmer,Jeanette C Papp,Neil H Parker,Loren Dm Pena,John A Phillips 3rd,Jennifer E Posey,John H Postlethwait,Lorraine Potocki,Barbara N Pusey,Genecee Renteria,Lynette Rives,Amy K Robertson,Lance H Rodan,Jill A Rosenfeld,Jacinda B Sampson,Susan L Samson,Kelly Schoch,Daryl A Scott,Lisa Shakachite,Prashant Sharma,Vandana Shashi,Rebecca Signer,Edwin K Silverman,Janet S Sinsheimer,Rebecca C Spillmann,Joan M Stoler,Nicholas Stong,Jennifer A Sullivan,David A Sweetser,Queenie K-G Tan,Cynthia J Tifft,Camilo Toro,Alyssa A Tran,Tiina K Urv,Eric Vilain,Tiphanie P Vogel,Daryl M Waggott,Colleen E Wahl,Nicole M Walley,Chris A Walsh,Melissa Walker,Jijun Wan,Michael F Wangler,Patricia A Ward,Katrina M Waters,Bobbie-Jo M Webb-Robertson,Monte Westerfield,Anastasia L Wise,Lynne A Wolfe,Elizabeth A Worthey,Shinya Yamamoto,John Yang,Yaping Yang,Amanda J Yoon,Guoyun Yu,Chunli Zhao,Allison Zheng,Kym Boycott,Alex MacKenzie,Jacek Majewski,Michael Brudno,Dennis Bulman,David Dyment

DOI: https://doi.org/10.1038/s41591-019-0457-8

Abstract:It is estimated that 350 million individuals worldwide suffer from rare diseases, which are predominantly caused by mutation in a single gene1. The current molecular diagnostic rate is estimated at 50%, with whole-exome sequencing (WES) among the most successful approaches2-5. For patients in whom WES is uninformative, RNA sequencing (RNA-seq) has shown diagnostic utility in specific tissues and diseases6-8. This includes muscle biopsies from patients with undiagnosed rare muscle disorders6,9, and cultured fibroblasts from patients with mitochondrial disorders7. However, for many individuals, biopsies are not performed for clinical care, and tissues are difficult to access. We sought to assess the utility of RNA-seq from blood as a diagnostic tool for rare diseases of different pathophysiologies. We generated whole-blood RNA-seq from 94 individuals with undiagnosed rare diseases spanning 16 diverse disease categories. We developed a robust approach to compare data from these individuals with large sets of RNA-seq data for controls (n = 1,594 unrelated controls and n = 49 family members) and demonstrated the impacts of expression, splicing, gene and variant filtering strategies on disease gene identification. Across our cohort, we observed that RNA-seq yields a 7.5% diagnostic rate, and an additional 16.7% with improved candidate gene resolution.